ABBVIE INC (1ABBV.MI) Stock Fundamental Analysis
Europe - BIT:1ABBV - US00287Y1091 - Common Stock
194.8 EUR
-6.2 (-3.08%)
Overall 1ABBV gets a fundamental rating of 5 out of 10. We evaluated 1ABBV against 76 industry peers in the Biotechnology industry. There are concerns on the financial health of 1ABBV while its profitability can be described as average. 1ABBV is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
1ABBV had positive earnings in the past year.
1ABBV had a positive operating cash flow in the past year.
In the past 5 years 1ABBV has always been profitable.
1ABBV had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
1ABBV has a Return On Assets of 2.71%. This is in the better half of the industry: 1ABBV outperforms 75.00% of its industry peers.
1ABBV's Return On Invested Capital of 13.81% is amongst the best of the industry. 1ABBV outperforms 89.47% of its industry peers.
The Average Return On Invested Capital over the past 3 years for 1ABBV is in line with the industry average of 13.32%.
The 3 year average ROIC (13.67%) for 1ABBV is below the current ROIC(13.81%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.71% | ||
| ROE | N/A | ||
| ROIC | 13.81% |
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
1.3 Margins
The Profit Margin of 1ABBV (6.38%) is better than 78.95% of its industry peers.
1ABBV's Profit Margin has declined in the last couple of years.
1ABBV has a Operating Margin of 31.27%. This is amongst the best in the industry. 1ABBV outperforms 89.47% of its industry peers.
In the last couple of years the Operating Margin of 1ABBV has declined.
With a decent Gross Margin value of 70.93%, 1ABBV is doing good in the industry, outperforming 64.47% of the companies in the same industry.
1ABBV's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.27% | ||
| PM (TTM) | 6.38% | ||
| GM | 70.93% |
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
2. Health
2.1 Basic Checks
1ABBV has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for 1ABBV remains at a similar level compared to 1 year ago.
Compared to 5 years ago, 1ABBV has more shares outstanding
Compared to 1 year ago, 1ABBV has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.41 indicates that 1ABBV is not a great score, but indicates only limited risk for bankruptcy at the moment.
1ABBV has a better Altman-Z score (2.41) than 61.84% of its industry peers.
The Debt to FCF ratio of 1ABBV is 3.86, which is a good value as it means it would take 1ABBV, 3.86 years of fcf income to pay off all of its debts.
1ABBV has a better Debt to FCF ratio (3.86) than 77.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.86 | ||
| Altman-Z | 2.41 |
ROIC/WACC1.52
WACC9.1%
2.3 Liquidity
1ABBV has a Current Ratio of 0.74. This is a bad value and indicates that 1ABBV is not financially healthy enough and could expect problems in meeting its short term obligations.
1ABBV's Current ratio of 0.74 is on the low side compared to the rest of the industry. 1ABBV is outperformed by 76.32% of its industry peers.
A Quick Ratio of 0.61 indicates that 1ABBV may have some problems paying its short term obligations.
1ABBV has a worse Quick ratio (0.61) than 77.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.74 | ||
| Quick Ratio | 0.61 |
3. Growth
3.1 Past
The earnings per share for 1ABBV have decreased by -1.03% in the last year.
The Earnings Per Share has been growing slightly by 2.51% on average over the past years.
The Revenue has been growing slightly by 6.05% in the past year.
Measured over the past years, 1ABBV shows a quite strong growth in Revenue. The Revenue has been growing by 11.11% on average per year.
EPS 1Y (TTM)-1.03%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%12.08%
Revenue 1Y (TTM)6.05%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%6.65%
3.2 Future
Based on estimates for the next years, 1ABBV will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.59% on average per year.
1ABBV is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.22% yearly.
EPS Next Y21.19%
EPS Next 2Y19.9%
EPS Next 3Y16.83%
EPS Next 5Y13.59%
Revenue Next Year8.21%
Revenue Next 2Y8.6%
Revenue Next 3Y8.22%
Revenue Next 5Y7.22%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 21.43, the valuation of 1ABBV can be described as rather expensive.
78.95% of the companies in the same industry are more expensive than 1ABBV, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of 1ABBV to the average of the S&P500 Index (27.69), we can say 1ABBV is valued slightly cheaper.
1ABBV is valuated correctly with a Price/Forward Earnings ratio of 15.61.
Based on the Price/Forward Earnings ratio, 1ABBV is valued cheaper than 85.53% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.18. 1ABBV is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.43 | ||
| Fwd PE | 15.61 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 1ABBV indicates a somewhat cheap valuation: 1ABBV is cheaper than 76.32% of the companies listed in the same industry.
1ABBV's Price/Free Cash Flow ratio is rather cheap when compared to the industry. 1ABBV is cheaper than 81.58% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 21.99 | ||
| EV/EBITDA | 17.34 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of 1ABBV may justify a higher PE ratio.
1ABBV's earnings are expected to grow with 16.82% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.01
PEG (5Y)8.54
EPS Next 2Y19.9%
EPS Next 3Y16.83%
5. Dividend
5.1 Amount
1ABBV has a Yearly Dividend Yield of 2.89%.
Compared to an average industry Dividend Yield of 8.16, 1ABBV pays a better dividend. On top of this 1ABBV pays more dividend than 94.74% of the companies listed in the same industry.
1ABBV's Dividend Yield is a higher than the S&P500 average which is at 2.34.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.89% |
5.2 History
The dividend of 1ABBV is nicely growing with an annual growth rate of 7.72%!
Dividend Growth(5Y)7.72%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
1ABBV pays out 304.54% of its income as dividend. This is not a sustainable payout ratio.
1ABBV's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP304.54%
EPS Next 2Y19.9%
EPS Next 3Y16.83%
BIT:1ABBV (10/15/2025, 7:00:00 PM)
194.8
-6.2 (-3.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners74.42%
Inst Owner ChangeN/A
Ins Owners0.05%
Ins Owner ChangeN/A
Market Cap344.13B
Analysts79.46
Price Target197.82 (1.55%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.89% |
Yearly Dividend5.35
Dividend Growth(5Y)7.72%
DP304.54%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.04%
Min EPS beat(2)0.95%
Max EPS beat(2)1.14%
EPS beat(4)4
Avg EPS beat(4)0.75%
Min EPS beat(4)0.02%
Max EPS beat(4)1.14%
EPS beat(8)7
Avg EPS beat(8)0.76%
EPS beat(12)9
Avg EPS beat(12)0.46%
EPS beat(16)11
Avg EPS beat(16)0.4%
Revenue beat(2)2
Avg Revenue beat(2)0.93%
Min Revenue beat(2)0.63%
Max Revenue beat(2)1.23%
Revenue beat(4)2
Avg Revenue beat(4)0.24%
Min Revenue beat(4)-0.71%
Max Revenue beat(4)1.23%
Revenue beat(8)4
Avg Revenue beat(8)0.36%
Revenue beat(12)5
Avg Revenue beat(12)-0.32%
Revenue beat(16)5
Avg Revenue beat(16)-0.81%
PT rev (1m)4.92%
PT rev (3m)5.18%
EPS NQ rev (1m)-15.4%
EPS NQ rev (3m)-13.81%
EPS NY rev (1m)-0.06%
EPS NY rev (3m)-1.83%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.44%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)1.26%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.43 | ||
| Fwd PE | 15.61 | ||
| P/S | 6.88 | ||
| P/FCF | 21.99 | ||
| P/OCF | 20.8 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 17.34 |
EPS(TTM)9.09
EY4.67%
EPS(NY)12.48
Fwd EY6.41%
FCF(TTM)8.86
FCFY4.55%
OCF(TTM)9.37
OCFY4.81%
SpS28.33
BVpS-0.09
TBVpS-45.1
PEG (NY)1.01
PEG (5Y)8.54
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.71% | ||
| ROE | N/A | ||
| ROCE | 18.72% | ||
| ROIC | 13.81% | ||
| ROICexc | 14.74% | ||
| ROICexgc | 370.81% | ||
| OM | 31.27% | ||
| PM (TTM) | 6.38% | ||
| GM | 70.93% | ||
| FCFM | 31.27% |
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
ROICexc(3y)15.06%
ROICexc(5y)13.91%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)17.54%
ROCE(5y)16.27%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y-1.81%
ROICexc growth 5Y-14.87%
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
F-Score6
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.86 | ||
| Debt/EBITDA | 2.58 | ||
| Cap/Depr | 12.62% | ||
| Cap/Sales | 1.79% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 72.74% | ||
| Profit Quality | 489.9% | ||
| Current Ratio | 0.74 | ||
| Quick Ratio | 0.61 | ||
| Altman-Z | 2.41 |
F-Score6
WACC9.1%
ROIC/WACC1.52
Cap/Depr(3y)9.59%
Cap/Depr(5y)10.06%
Cap/Sales(3y)1.45%
Cap/Sales(5y)1.5%
Profit Quality(3y)361.43%
Profit Quality(5y)328.91%
High Growth Momentum
Growth
EPS 1Y (TTM)-1.03%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%12.08%
EPS Next Y21.19%
EPS Next 2Y19.9%
EPS Next 3Y16.83%
EPS Next 5Y13.59%
Revenue 1Y (TTM)6.05%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%6.65%
Revenue Next Year8.21%
Revenue Next 2Y8.6%
Revenue Next 3Y8.22%
Revenue Next 5Y7.22%
EBIT growth 1Y13.81%
EBIT growth 3Y-5.38%
EBIT growth 5Y3.87%
EBIT Next Year20.95%
EBIT Next 3Y15.22%
EBIT Next 5Y11.27%
FCF growth 1Y-26.45%
FCF growth 3Y-6.75%
FCF growth 5Y6.9%
OCF growth 1Y-24.5%
OCF growth 3Y-6.19%
OCF growth 5Y7.14%